Open Outbreak

Oropouche fever

Also known as: Oropouche virus, OROV, Oropouche virus disease

Oropouche fever is an infection caused by Oropouche virus, an arbovirus spread mainly by bites from tiny midges and sometimes mosquitoes. It has been reported mostly in tropical parts of the Americas, especially the Amazon region, but WHO noted wider spread in 2024, including places with no previously recognized history of the disease. Illness usually starts suddenly with fever, headache, muscle pain, joint pain, and vomiting. WHO says the incubation period is usually 4 to 8 days, with a reported range of 3 to 12 days. Most descriptions focus on a febrile illness, but some patients develop aseptic meningitis, and WHO reported deaths and possible mother-to-baby transmission under investigation in Brazil in 2024. There is no evidence of direct human-to-human spread in the WHO outbreak notices reviewed here. No licensed specific treatment or vaccine was identified in the sources used here; care is supportive. Because symptoms overlap with dengue and other mosquito-borne diseases, testing and local vector surveillance matter.

Key facts

TransmissionPrimarily through bites of infected Culicoides paraensis midges; mosquitoes are also described in WHO and review sources. No direct human-to-human transmission documented in the WHO notices reviewed here.
IncubationUsually 4–8 days; reported range 3–12 days (WHO, 2016).
Case fatalityUnknown overall. In the WHO Region of the Americas, 2 deaths were reported among 8,078 confirmed cases in 2024 as of 2024-07-20.
Reproduction numberunknown
VaccineNo licensed vaccine identified in the sources reviewed.
TreatmentNo specific antiviral identified in the sources reviewed; treatment is supportive.
ReservoirZoonotic cycle involving wild animals; encyclopedia source lists sloths, non-human primates, and birds.
Endemic regionsHistorically the Amazon region of the Americas; outbreaks and cases have been reported in Brazil, Peru, Bolivia, Colombia, Cuba, Ecuador, French Guiana, Panama, Trinidad and Tobago, and others in the Region of the Americas.

Transmission

Oropouche fever is spread mainly by the bite of infected midges, especially Culicoides paraensis. WHO also describes mosquito bites as a route in some settings. The disease is zoonotic, meaning the virus circulates in animals and then reaches people through biting insects. A review source describes both urban and sylvatic, or forest, transmission cycles. In the urban cycle, people can be infected where competent biting insects are present. In the forest cycle, the virus is maintained in wildlife and arthropods. The WHO outbreak notices reviewed here are clear on one important point for worried readers: there is no documented direct person-to-person transmission. That means ordinary casual contact is not the known route. The main practical risk is exposure to biting insects in affected areas, especially where surveillance has found local transmission.

Symptoms and severity

WHO says Oropouche virus disease is a febrile illness. Reported symptoms include sudden high fever, headache, muscle pain, joint pain, and vomiting. These symptoms overlap with dengue and other tropical infections, so the illness can be mistaken for something else without testing. WHO's 2016 Peru notice gives an incubation period of 4 to 8 days, with a range of 3 to 12 days. Severity is still not fully defined in the sources reviewed here. WHO notes that some patients can develop aseptic meningitis, a type of inflammation around the brain not caused by typical bacteria. In 2024, WHO also reported two deaths among confirmed cases in the Americas and described possible vertical transmission in Brazil, including fetal deaths, miscarriage, stillbirths, and newborns with microcephaly under investigation. WHO stressed that causation was still being investigated.

Treatment and vaccines

The sources reviewed here do not identify a licensed vaccine for Oropouche fever. They also do not identify a specific antiviral drug that is established as standard treatment. In practice, that means care is supportive: managing fever, aches, dehydration, and other symptoms while watching for complications. Because the symptoms can look like dengue and other arboviral infections, laboratory confirmation matters, especially during outbreaks or in places where the disease is newly detected. WHO's 2024 regional notice describes Oropouche virus disease as an emerging and poorly identified arbovirus in the Americas, which helps explain why vaccine and treatment options are limited. For the public, the most useful protective steps are reducing bites from midges and mosquitoes and seeking medical advice if fever develops after being in an affected area. Pregnant patients may need particular attention because WHO reported possible vertical transmission under investigation in Brazil in 2024.

Where it occurs

WHO says Oropouche virus disease has occurred historically in the Amazon region, where the virus has shown persistent endemicity and periodic outbreaks. Older reports and review articles place it mainly in South and parts of Central America and the Caribbean. In 2024, WHO documented clear geographic expansion. By 2024-11-25, confirmed cases had been reported across ten countries and one territory in the Region of the Americas, and imported cases had also been reported in Canada, the United States, and countries in the European Region. The 2024 WHO notices specifically mention spread into areas with no previously recognized history of Oropouche virus disease, including Cuba, and transmission in both Amazonian and non-Amazonian states of Brazil. For readers, the key point is that this is no longer only a remote Amazon issue. It remains concentrated in the Americas, but the map is widening where suitable vectors and surveillance are present.

Recent history

This site's archive lists 4 WHO-linked historical events for Oropouche. In the archive returned here, the first is Peru on 2016-06-03, followed by French Guiana on 2020-10-13, then Cuba on 2024-06-11, and a wider regional update on 2024-08-23. WHO later published another regional update on 2024-12-05. The pattern is notable: earlier notices were more localized, while 2024 brought a broader regional event with many more confirmed infections and spread into places without a recognized previous history. WHO reported 8,078 confirmed cases and 2 deaths in the Americas as of 2024-07-20, then 11,634 confirmed cases and 2 deaths as of 2024-11-25, across ten countries and one territory. WHO assessed the risk as high at the regional level and low at the global level in the 2024 regional notice. That combination suggests a real regional public-health problem, but not a global emergency on the evidence reviewed here.

What to watch

Several signals would make Oropouche fever more concerning. First, sustained spread into new countries or large urban areas would matter, especially where people have little prior exposure and surveillance is weak. Second, any good evidence of direct human-to-human transmission would be a major change; the WHO notices reviewed here say this has not been documented. Third, stronger evidence that infection during pregnancy causes fetal harm or birth defects would raise the stakes for public-health advice and antenatal care. Fourth, increases in severe disease or deaths would matter because the overall case-fatality picture is still unclear in the sources used here. Fifth, the absence of a licensed vaccine or specific antiviral means control relies heavily on vector surveillance, diagnosis, and bite prevention; shortages in diagnostic capacity or vector-control resources could worsen outbreaks. Finally, imported cases outside the Americas are worth watching because they can reveal wider travel-linked spread and test whether local vectors could support transmission.

Updated